Search

Your search keyword '"Fredriksson, Martin"' showing total 306 results

Search Constraints

Start Over You searched for: Author "Fredriksson, Martin" Remove constraint Author: "Fredriksson, Martin" Publication Year Range Last 10 years Remove constraint Publication Year Range: Last 10 years
306 results on '"Fredriksson, Martin"'

Search Results

2. Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial

4. CODE-EHR best-practice framework for the use of structured electronic health-care records in clinical research

5. Moral rights and the protection of classics: A study of §51 in the Swedish Copyright Act of 1960.

7. Protecting the classics in Swedish copyright law : intellectual property as a cultural policy tool

8. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial

10. Authors, Inventors and Entrepreneurs: Intellectual Property and Actors of Extraction

11. Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes

12. Abstract 15701: Relationship Between Cardiac Biomarkers and Major Adverse Cardiovascular Events in DECLARE-TIMI 58

14. Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58

16. Commentary on: Swedish Ordinance on the Limitation of Terms of Protection (1841)

17. Commentary on: Swedish freedom of the Press Ordinance (1810)

18. Commentary on: Swedish Copyright Act (1877)

19. Mediatised marketplaces: Platforms, places, and strategies for trading material goods in digital economies

21. Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction: Subanalysis From the DECLARE-TIMI 58 Trial

22. Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes A Secondary Analysis of the DECLARE-TIMI 58 Trial

23. CODE-EHR best practice framework for the use of structured electronic healthcare records in clinical research

24. Dapagliflozin and prevention of kidney disease among patients with type 2 diabetes– post hoc analyses from the DECLARE-TIMI 58 trial

26. Epilogue

29. CODE-EHR best practice framework for the use of structured electronic healthcare records in clinical research

30. Balancing community rights and national interests in international protection of traditional knowledge : a study of India’s Traditional Knowledge Digital Library

31. CODE-EHR best practice framework for the use of structured electronic healthcare records in clinical research

32. Political parties and organization studies : The party as a critical case of organizing

33. A Reflection on the Cultural Significance of the Protection of Classics

34. CODE-EHR best practice framework for the use of structured electronic healthcare records in clinical research

35. Open Source Seeds and the Revitalization of Local Knowledge

37. The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58

38. Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial.

40. Welcome to the party

41. India’s Traditional Knowledge Digital Library and the Politics of Patent Classifications

42. Dilemmas of Protection : Decolonising the Regulation of Genetic resources and Cultural Heritage

44. Dilemmas of Protection : Decolonising the Regulation of Genetic resources and Cultural Heritage

45. Pirate Utopia Revisited

46. Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium–glucose co‐transporter 2 inhibitor therapy in DECLARE‐TIMI 58

48. Cardiorenal outcomes with dapagliflozin by baseline glucose‐lowering agents: Post hoc analyses from DECLARE‐TIMI 58

49. 303-OR: Effect of Dapagliflozin on Risk for Fast Decline in EGFR: Analyses from the DECLARE-TIMI 58 Trial

50. 1101-P: Cardiorenal Outcomes with Dapagliflozin by Baseline Glucose Lowering Agents: Analyses from DECLARE-TIMI 58

Catalog

Books, media, physical & digital resources